{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T05:36:01Z","timestamp":1777354561333,"version":"3.51.4"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T00:00:00Z","timestamp":1610496000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.ijid.2021.01.034","type":"journal-article","created":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T04:27:42Z","timestamp":1611894462000},"page":"610-616","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Characterization of antibodies in human immunoglobulin products from different regions worldwide"],"prefix":"10.1016","volume":"104","author":[{"given":"Alexandra","family":"Serra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N\u00faria","family":"Marzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Berta","family":"Pons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pau","family":"Maduell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maite","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvador","family":"Grancha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2021.01.034_bib0005","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jcv.2014.06.003","article-title":"West Nile encephalitis outbreak in Kerala, India, 2011","volume":"61","author":"Anukumar","year":"2014","journal-title":"J Clin Virol"},{"key":"10.1016\/j.ijid.2021.01.034_bib0010","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1086\/506363","article-title":"Measles-virus-neutralizing antibodies in intravenous immunoglobulins","volume":"194","author":"Audet","year":"2006","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijid.2021.01.034_bib0015","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1080\/14787210.2017.1328278","article-title":"Use of human immunoglobulins as an anti-infective treatment: the experience so far and their possible re-emerging role","volume":"15","author":"Bozzo","year":"2017","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.ijid.2021.01.034_bib0020","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1542\/peds.9.6.722","article-title":"Agammaglobulinemia","volume":"9","author":"Bruton","year":"1952","journal-title":"Pediatrics"},{"key":"10.1016\/j.ijid.2021.01.034_bib0025","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaa102","article-title":"High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with Coronavirus Disease 2019","volume":"7","author":"Cao","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijid.2021.01.034_bib0030","doi-asserted-by":"crossref","first-page":"571","DOI":"10.2217\/imt-2020-0095","article-title":"Currently available intravenous immunoglobulin contains antibodies reacting against severe acute respiratory syndrome coronavirus 2 antigens","volume":"12","author":"D\u00edez","year":"2020","journal-title":"Immunotherapy"},{"key":"10.1016\/j.ijid.2021.01.034_bib0035","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.jaci.2009.09.008","article-title":"Hepatitis A virus antibodies in immunoglobulin preparations","volume":"125","author":"Farcet","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.ijid.2021.01.034_bib0040","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1016\/j.vaccine.2019.04.022","article-title":"Measles virus neutralizing antibodies in immunoglobulin lots produced from plasma collected in Europe or the United States","volume":"37","author":"Farcet","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.ijid.2021.01.034_bib0045","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1467-842X.2005.tb00748.x","article-title":"National serosurvey of poliovirus immunity in Australia, 1996-99","volume":"29","author":"Gidding","year":"2005","journal-title":"Aust N Z J Public Health"},{"key":"10.1016\/j.ijid.2021.01.034_bib0050","first-page":"675","article-title":"Analysis of specific IgG titers against tick-borne encephalitis in patients with primary antibody deficiency under immunoglobulin substitution therapy: impact of plasma donor origin","volume":"5","author":"Goldacker","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.ijid.2021.01.034_bib0055","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1136\/jech-2017-210296","article-title":"Socioeconomic inequalities in child vaccination in low\/middle-income countries: what accounts for the differences?","volume":"72","author":"Hajizadeh","year":"2018","journal-title":"J Epidemiol Community Health"},{"key":"10.1016\/j.ijid.2021.01.034_bib0060","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/INF.0b013e3181f127be","article-title":"Cross-reactive neutralizing antibody against pandemic 2009 H1N1 influenza a virus in intravenous immunoglobulin preparations","volume":"30","author":"Hong","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.ijid.2021.01.034_bib0065","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1365-2249.2009.03953.x","article-title":"Flebogamma\u00ae 5% DIF development: rationale for a new option in intravenous immunoglobulin therapy","volume":"157","author":"Jorquera","year":"2009","journal-title":"Clin Exper Immunol"},{"key":"10.1016\/j.ijid.2021.01.034_bib0070","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1128\/CMR.13.4.602","article-title":"Passive immunity in prevention and treatment of infectious diseases","volume":"13","author":"Keller","year":"2000","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijid.2021.01.034_bib0075","first-page":"245","article-title":"Significant neutralizing activities against H2N2 influenza A viruses in human intravenous immunoglobulin lots manufactured from 1993 to 2010","volume":"6","author":"Kubota-Koketsu","year":"2012","journal-title":"Biologics"},{"key":"10.1016\/j.ijid.2021.01.034_bib0080","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.molimm.2004.07.046","article-title":"Therapeutic intravenous immunoglobulins","volume":"42","author":"Lemieux","year":"2005","journal-title":"Molecular Immunology"},{"key":"10.1016\/j.ijid.2021.01.034_bib0085","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3201\/eid1802.111648","article-title":"Risk for emergence of dengue and chikungunya virus in Israel","volume":"18","author":"Leshem","year":"2012","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.ijid.2021.01.034_bib0090","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","article-title":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding","volume":"395","author":"Lu","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ijid.2021.01.034_bib0095","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1001\/jamapediatrics.2017.1965","article-title":"Evaluation of Combination Measles-Mumps-Rubella-Varicella Vaccine Introduction in Australia","volume":"171","author":"Macartney","year":"2017","journal-title":"JAMA Pediatrics"},{"key":"10.1016\/j.ijid.2021.01.034_bib0100","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2009-0047","article-title":"Varicella-specific immunoglobulin G titers in commercial intravenous immunoglobulin preparations","volume":"124","author":"Maranich","year":"2009","journal-title":"Pediatrics"},{"key":"10.1016\/j.ijid.2021.01.034_bib0105","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ijid.2021.01.034_bib0110","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/vox.12246","article-title":"In vitro evaluation of cytomegalovirus-specific hyperimmune globulins vs. standard intravenous immunoglobulins","volume":"109","author":"Miescher","year":"2015","journal-title":"Vox Sang"},{"key":"10.1016\/j.ijid.2021.01.034_bib0115","first-page":"1158","article-title":"Characterization of antibodies to capsular polysaccharide antigens of Haemophilus influenzae type b and Streptococcus pneumoniae in human immune globulin intravenous preparations","volume":"11","author":"Mikolajczyk","year":"2004","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.ijid.2021.01.034_bib0120","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1248\/yakushi1947.114.12_972","article-title":"[Protective effect and antibody titer of intravenous immunoglobulin (IVIG) against clinical isolates of opportunistic bacteria]","volume":"114","author":"Nakae","year":"1994","journal-title":"Yakugaku Zasshi"},{"key":"10.1016\/j.ijid.2021.01.034_bib0125","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1471-2172-15-26","article-title":"Antibody levels to tetanus, diphtheria, measles and varicella in patients with primary immunodeficiency undergoing intravenous immunoglobulin therapy: a prospective study","volume":"15","author":"Nobre","year":"2014","journal-title":"BMC Immunol"},{"key":"10.1016\/j.ijid.2021.01.034_bib0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2016.09.023","article-title":"Update on the use of immunoglobulin in human disease: a review of evidence","volume":"139","author":"Perez","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.ijid.2021.01.034_bib0135","series-title":"Climate Classification and Climatic Regions of the World. Fundamentals of Physical Geography","author":"Pidwirny","year":"2006"},{"key":"10.1016\/j.ijid.2021.01.034_bib0140","series-title":"World Economic Forum. Which countries have the most immigrants?","author":"Pison","year":"2019"},{"key":"10.1016\/j.ijid.2021.01.034_bib0145","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/jmv.21980","article-title":"Neutralization of different echovirus serotypes by individual lots of intravenous immunoglobulin","volume":"83","author":"Planitzer","year":"2011","journal-title":"J Med Virol"},{"key":"10.1016\/j.ijid.2021.01.034_bib0150","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/TP.0b013e318224115e","article-title":"Cytomegalovirus neutralization by hyperimmune and standard intravenous immunoglobulin preparations","volume":"92","author":"Planitzer","year":"2011","journal-title":"Transplantation"},{"key":"10.1016\/j.ijid.2021.01.034_bib0155","article-title":"Virus evolution and transmission in an ever more connected world","volume":"282","author":"Pybus","year":"2015","journal-title":"Proc Biol Sci"},{"key":"10.1016\/j.ijid.2021.01.034_bib0160","doi-asserted-by":"crossref","DOI":"10.2807\/ese.16.10.19812-en","article-title":"Increasing West Nile virus antibody titres in central European plasma donors from 2006 to 2010","volume":"16","author":"Rabel","year":"2011","journal-title":"Euro Surveill"},{"key":"10.1016\/j.ijid.2021.01.034_bib0165","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1128\/CVI.05705-11","article-title":"Tick-borne encephalitis virus-neutralizing antibodies in different immunoglobulin preparations","volume":"19","author":"Rabel","year":"2012","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.ijid.2021.01.034_bib0170","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1423-0410.2009.01226.x","article-title":"Intravenous immunoglobulin G: trends in production methods, quality control and quality assurance","volume":"98","author":"Radosevich","year":"2010","journal-title":"Vox Sang"},{"key":"10.1016\/j.ijid.2021.01.034_bib0175","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s15010-012-0323-9","article-title":"Review of intravenous immunoglobulin replacement therapy trials for primary humoral immunodeficiency patients","volume":"40","author":"Schroeder","year":"2012","journal-title":"Infection"},{"key":"10.1016\/j.ijid.2021.01.034_bib0180","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1248\/yakushi.130.977","article-title":"Measurement and assessment of cytomegalovirus of immunoglobulin (Ig) g titer in preparations","volume":"130","author":"Shibaguchi","year":"2010","journal-title":"Yakugaku Zasshi"},{"key":"10.1016\/j.ijid.2021.01.034_bib0185","first-page":"217","article-title":"Heterosubtypic anti-avian H5N1 influenza antibodies in intravenous immunoglobulins from globally separate populations protect against H5N1 infection in cell culture","volume":"3","author":"Sullivan","year":"2009","journal-title":"J Mol Genet Med"},{"key":"10.1016\/j.ijid.2021.01.034_bib0190","doi-asserted-by":"crossref","first-page":"803","DOI":"10.21037\/jtd.2016.03.29","article-title":"Prevalence of neutralizing antibodies to common respiratory viruses in intravenous immunoglobulin and in healthy donors in southern China","volume":"8","author":"Tian","year":"2016","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.ijid.2021.01.034_bib0195","series-title":"Human Development Report","doi-asserted-by":"crossref","DOI":"10.18356\/838f78fd-en","author":"United Nations Development Programme","year":"2019"},{"key":"10.1016\/j.ijid.2021.01.034_bib0200","author":"US Food and Drug Administration","year":"2020"},{"key":"10.1016\/j.ijid.2021.01.034_bib0205","series-title":"USP Official Monograph (USP 40): Immune globulin","author":"US Pharmacopoeia","year":"2017"},{"key":"10.1016\/j.ijid.2021.01.034_bib0210","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.autrev.2008.04.011","article-title":"Role of natural antibodies in immune homeostasis: IVIg perspective","volume":"7","author":"Vani","year":"2008","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.ijid.2021.01.034_bib0215","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1055\/s-0029-1207589","article-title":"Ueber das zustandekommen der diphtherie-immunit\u00e4t und der tetanus-immunit\u00e4t bei thieren","volume":"16","author":"von Behring","year":"1890","journal-title":"Dtsch Med Wochenschr"},{"key":"10.1016\/j.ijid.2021.01.034_bib0220","first-page":"201","article-title":"[Neutralizing virus antibodies in human immunoglobulins for intravenous use]","volume":"12","author":"Weeke-Luttmann","year":"1984","journal-title":"Immun Infekt"},{"key":"10.1016\/j.ijid.2021.01.034_bib0225","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.biologicals.2012.10.003","article-title":"Analyzing titers of antibodies against bacterial and viral antigens, and bacterial toxoids in the intravenous immunoglobulins utilized in Taiwan","volume":"41","author":"Wu","year":"2013","journal-title":"Biologicals"},{"key":"10.1016\/j.ijid.2021.01.034_bib0230","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jinf.2020.03.044","article-title":"Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID-19","volume":"81","author":"Xie","year":"2020","journal-title":"J Infect"},{"key":"10.1016\/j.ijid.2021.01.034_bib0235","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1080\/21645515.2016.1234554","article-title":"Do Australian immunoglobulin products meet international measles antibody titer standards?","volume":"13","author":"Young","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.ijid.2021.01.034_bib0240","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1080\/21645515.2017.1327110","article-title":"Rubella antibodies in Australian immunoglobulin products","volume":"13","author":"Young","year":"2017","journal-title":"Hum Vaccin Immunother"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971221000412?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971221000412?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T08:00:50Z","timestamp":1761120050000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971221000412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":48,"alternative-id":["S1201971221000412"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2021.01.034","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization of antibodies in human immunoglobulin products from different regions worldwide","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2021.01.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}]}}